Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers.

Hey Soo KimOidov BaatarkhuuHye Won LeeJun Yong ParkDo Young KimSang Hoon AhnKijun SongKwang-Hyub HanBeom Kyung KimSeung-Up Kim

Published in: Liver international : official journal of the International Association for the Study of the Liver (2018)

After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis.

Keyphrases

drug induced
liver injury
liver fibrosis
hepatitis b virus
oxidative stress
sars cov
hiv infected
antiretroviral therapy
adverse drug
hiv infected patients
risk factors
virtual reality
type diabetes
insulin resistance